Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document a foreign private issuer with ordinary shares and listed warrants, using Form 6-K reports to disclose material events, Nasdaq listing-compliance notices, capital actions, securities purchase agreements and warrant matters. The filings include disclosures on a board-approved reverse stock split, adjustments to warrant terms, a registered ordinary-share offering under a Form F-3 shelf registration statement, and the repurchase and cancellation of a warrant.
EUDA's regulatory reports also describe its healthcare activities in Asia, including a non-exclusive arrangement to market selected Shenzhen Inno immunotherapies to customers in Malaysia through CK Health Plus Sdn Bhd, with treatments conducted in China.
EUDA Health Holdings Limited describes a planned collaboration under a non-binding Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. The parties plan to combine GO POSB’s induced pluripotent stem cell platform and universal tumor organoid bank with SIIT’s Natural Killer and NK-TCR cell engineering and GMP manufacturing capabilities to explore off-the-shelf cell therapies for wellness and oncology.
The initiative targets future global distribution, subject to definitive agreements, sufficient funding, manufacturing, testing, clinical evaluation and regulatory approvals. EUDA positions this program within its strategy as a distributor of wellness and non-invasive healthcare products in Asia, aiming to address the needs of over 1.8 billion people in a region where more than 30% of the population is rapidly aging.
EUDA Health Holdings Limited entered into a tri-party Memorandum of Understanding with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. to collaborate on next-generation therapies derived from induced pluripotent stem cells, including NK-TCR cell therapies.
The company states this collaboration is a significant milestone that aligns with its strategy to strengthen commercialization and distribution of innovative, science-backed wellness and non-invasive healthcare products and services. EUDA focuses on Singapore, Malaysia and China and aims to serve over 1.8 billion people in a region where more than 30% of the population is rapidly aging, with an emphasis on the longevity sector.
Euda Health Holdings Limited reports that it has terminated its at-the-market equity offering program and the related At The Market Offering Agreement with Chardan Capital Markets, LLC. The program had previously allowed sales of ordinary shares with an aggregate offering price of up to $10.0 million, but this capacity had been reduced to zero and no ordinary shares were sold. All related prospectus supplements are also terminated as of the date of this supplement. The company’s ordinary shares trade on the NASDAQ Capital Market under the symbol EUDA, and the closing price was $15.30 on July 21, 2026.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.
EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.
EUDA Health Holdings Ltd reports an amended Schedule 13G showing beneficial ownership by Tan Meng Dong (James) and 8i Capital Limited. Mr. Tan beneficially owns 459,130 ordinary shares, equal to 15.3% of the outstanding ordinary shares; this total includes 340,631 shares held directly, 111,193 shares held by 8i Capital Limited, and 7,306 shares underlying warrants. The filing states 2,994,325 ordinary shares outstanding as of May 22, 2026. The statement notes that Mr. Tan is sole shareholder and director of 8i Capital Limited and that the parties filed a Joint Filing Agreement to report ownership jointly.
EUDA Health Holdings Ltd Schedule 13G reports that Zhang Xin beneficially owns 295,000 ordinary shares, representing 9.85% of the class. The filing states shares outstanding were 2,994,325 ordinary shares as of May 22, 2026.
The filing lists sole voting and sole dispositive power over the 295,000 shares. The document is a passive ownership disclosure under Schedule 13G and does not describe transactions or transfers within the excerpt.
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
EUDA Health Holdings Limited reported that it has regained compliance with the Nasdaq Capital Market’s continued listing requirements related to market value. Nasdaq had previously notified EUDA on April 23, 2026 that its Market Value of Listed Securities was below the required $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). A subsequent Nasdaq notice on May 28, 2026 confirmed that EUDA’s Market Value of Listed Securities was $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, restoring the Company’s compliance with the MVLS standard.